The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, BMS, Galapagos, Johnson & Johnson and Takeda. These supporters have no influence over the production of the content.
EHA 2021 | Unmet needs in Hodgkin lymphoma
Julia Driessen
• 4 Jun 2021
Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, comments on the improving cure rates for patients with Hodgkin lymphoma, highlighting the need for improved treatment regimens for older patients and the potential role of brentuximab vedotin and PD-1 inhibitors, as well as the need to improve the balance between efficacy and toxicity. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
